Pay in 4 interest-free payments of $7.09 Learn more
Ships within 48 hours · Estimated delivery Nov 4 - Nov 9
A single ascending dose, first-in-human phase 1 study to assess the safety and pharmacokinetic profile of LY3437943 was performed on 47 healthy participants (ClinicalTrials.gov, NCT03841630)
Research into the role that CJC-1295 may play in muscle building is pending
How do I book
From what we know now, it would significantly raise the cost of coverage for our employer groups and our members, says Matt Burns, chief actuary at Blue Cross and Blue Shield of Kansas
US$ 26.98
US$ 21.32
US$ 22.03
US$ 24.49
